Macquarie Group’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,620,912
Closed -$101M 1310
2025
Q3
$101M Sell
1,620,912
-346,311
-18% -$24.1M 0.12% 225
2025
Q2
$157M Sell
1,967,223
-285,267
-13% -$23.9M 0.19% 105
2025
Q1
$194M Sell
2,252,490
-56,527
-2% -$4.64M 0.24% 88
2024
Q4
$180M Sell
2,309,017
-365,467
-14% -$28.4M 0.22% 97
2024
Q3
$193M Sell
2,674,484
-162,363
-6% -$11.5M 0.21% 109
2024
Q2
$195M Sell
2,836,847
-83,067
-3% -$5.63M 0.22% 105
2024
Q1
$212M Sell
2,919,914
-142,708
-5% -$9.54M 0.24% 95
2023
Q4
$187M Sell
3,062,622
-57,576
-2% -$3.42M 0.22% 108
2023
Q3
$178M Buy
3,120,198
+51,589
+2% +$3.12M 0.22% 102
2023
Q2
$182M Buy
3,068,609
+315,178
+11% +$18.9M 0.21% 115
2023
Q1
$172M Buy
2,753,431
+781,431
+40% +$48.8M 0.2% 112
2022
Q4
$123M Buy
1,972,000
+50,677
+3% +$2.91M 0.15% 186
2022
Q3
$95.8M Buy
1,921,323
+33,844
+2% +$1.87M 0.12% 237
2022
Q2
$111M Buy
1,887,479
+79,519
+4% +$4.38M 0.12% 216
2022
Q1
$95.7K Buy
1,807,960
+33,362
+2% +$1.93M 0.07% 305
2021
Q4
$108M Buy
1,774,598
+29,552
+2% +$1.75M 0.09% 286
2021
Q3
$97.9M Buy
1,745,046
+17,180
+1% +$944K 0.08% 307
2021
Q2
$90M Buy
1,727,866
+30,530
+2% +$1.47M 0.07% 331
2021
Q1
$74.8M Sell
1,697,336
-107,993
-6% -$4.54M 0.11% 239
2020
Q4
$63M Buy
1,805,329
+6,029
+0.3% +$214K 0.09% 259
2020
Q3
$65.5M Buy
1,799,300
+24,033
+1% +$894K 0.11% 198
2020
Q2
$66.7M Buy
1,775,267
+100,814
+6% +$4.03M 0.11% 188
2020
Q1
$61.4M Sell
1,674,453
-327,127
-16% -$12.7M 0.13% 154
2019
Q4
$81.1M Buy
2,001,580
+251,580
+14% +$9.38M 0.12% 167
2019
Q3
$60.7M Buy
1,750,000
+44,019
+3% +$1.45M 0.1% 205
2019
Q2
$54M Buy
1,705,981
+122,956
+8% +$3.65M 0.09% 243
2019
Q1
$47.3M Buy
1,583,025
+136,700
+9% +$3.92M 0.08% 267
2018
Q4
$44.7M Buy
1,446,325
+216,570
+18% +$7.9M 0.09% 247
2018
Q3
$46.6M Buy
1,229,755
+259,248
+27% +$9.81M 0.08% 281
2018
Q2
$37.2M Buy
970,507
+106,565
+12% +$3.59M 0.06% 330
2018
Q1
$29.1M Buy
863,942
+162,070
+23% +$6.22M 0.05% 375
2017
Q4
$31.2M Buy
701,872
+73,293
+12% +$3.34M 0.06% 358
2017
Q3
$31.5M Buy
628,579
+76,168
+14% +$3.89M 0.06% 346
2017
Q2
$29.2M Buy
552,411
+82,317
+18% +$4.41M 0.05% 342
2017
Q1
$26.1M Buy
470,094
+62,089
+15% +$3.42M 0.05% 388
2016
Q4
$21.3M Buy
408,005
+102,610
+34% +$4.95M 0.04% 419
2016
Q3
$14.7M Sell
305,395
-277,583
-48% -$14M 0.03% 509
2016
Q2
$32.3M Buy
582,978
+342,160
+142% +$18.8M 0.03% 437
2016
Q1
$12.9M Buy
240,818
+30,284
+14% +$1.49M 0.03% 476
2015
Q4
$10.8M Sell
210,534
-53,462
-20% -$2.66M 0.02% 519
2015
Q3
$11.9M Buy
263,996
+52,132
+25% +$2.46M 0.03% 468
2015
Q2
$9.8M Buy
211,864
+30,777
+17% +$1.35M 0.02% 554
2015
Q1
$7.77M Buy
181,087
+36,870
+26% +$1.41M 0.02% 616
2014
Q4
$5.01M Sell
144,217
-20,084
-12% -$666K 0.01% 721
2014
Q3
$5.32M Buy
164,301
+21,856
+15% +$731K 0.01% 696
2014
Q2
$4.83M Sell
142,445
-33,170
-19% -$1.06M 0.01% 715
2014
Q1
$4.79M Buy
175,615
+35,085
+25% +$1.04M 0.01% 687
2013
Q4
$5.03M Buy
140,530
+51,280
+57% +$1.7M 0.01% 636
2013
Q3
$2.69M Sell
89,250
-3,610
-4% -$118K 0.01% 809
2013
Q2
$2.71M Buy
+92,860
New +$2.62M 0.01% 777

Other funds holding PBH

Macquarie Group's PBH Position: Q4 2025 in Review

Macquarie Group sold out of Prestige Consumer Healthcare (PBH) in Q4 2025, closing a stake of 1,620,912 shares — an estimated $101M sold.

Macquarie Group first reported a position in PBH in Q2 2013 and held it in 50 quarters. The position peaked at $212M in Q1 2024. 354 funds tracked by Wall St. Rank hold PBH as of Q4 2025.

  • Macquarie Group reported no remaining Prestige Consumer Healthcare position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 1,620,912 Prestige Consumer Healthcare shares in Q4 2025, an estimated $101M.
  • Macquarie Group first reported a position in Prestige Consumer Healthcare in Q2 2013 and held it in 50 quarters.
  • Macquarie Group's Prestige Consumer Healthcare position peaked at $212M in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.